Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 1;34(7):1095-1099.
doi: 10.1097/QAD.0000000000002530.

Who are the persons living with HIV who might refuse to participate in HIV cure-related clinical trials with treatment interruption?

Christel Protiere  1   2 , Marion Fiorentino  1   2 , Abdourahmane Sow  1   2 , Marie Préau  3 , Marion Mora  1   2 , Lisa Fressard  2   4   5 , Laurence Meyer  6 , Jean-Daniel Lelièvre  7   8   9 , Olivier Lambotte  10   11   12   13 , Bruno Spire  1   2 , Marie Suzan-Monti  1   2
Affiliations

Who are the persons living with HIV who might refuse to participate in HIV cure-related clinical trials with treatment interruption?

Christel Protiere et al. AIDS. .

Abstract

: Achieving a HIV cure has become a research priority. As any improvement of knowledge, which could help scientists design new HIV cure-related clinical trials (HCRCT) depends on the risks potential participants are willing to accept, it is important to understand who will agree or refuse to participate and in which proportions. By providing insights into factors associated with reluctance toward HCRCT participation, our results may help clinicians in patient recruitment.

PubMed Disclaimer

References

    1. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
    1. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. Lancet HIV 2019; 6:e259–e268.
    1. Palich R, Ghosn J, Chaillon A, Boilet V, Nere M-L, Chaix M-L, et al. VRI02/ANRS149 LIGHT Vaccine Trial GroupViral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial. AIDS 2019; 33:279–284.
    1. Ghosn J, Palich R, Chaillon A, Boilet V, Nere M, Delobel P, et al. VRI02/ANRS149 LIGHT Vaccine Trial GroupViral rebound in semen after treatment interruption in a HIV therapeutic vaccine double-blind trial (VRI02/ANRS149-LIGHT). J Int AIDS Soc 2017; 20:279–284.
    1. Lévy Y, Leliévre J-D, Perrier A, Boilet V, Bouchaud O, Girard P-M, et al. Preliminary Safety Results from the VRI02 ANRS 149 Light (Lipopeptide and DNA GTU HIV Therapeutic Trial). AIDS Res Hum Retroviruses 2016; 32:406.

Publication types

Substances